The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.
Buying's good for the acquirers, which should give other companies ideas.
The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.
'Blind side' competition is playing havoc with some highly visible companies, says Jim Cramer. You can't compete with free.